Abstract
About 100 transmittor substances have been identified in the human brain. It is known that most drugs used for the treatment of psychiatric, neurologic and pain disorders interact with one or several of the neurotransmission systems. The receptor subtypes and carrier proteins for transmitter transport across membranes as well as synthetic and metabolic enzymes are all potential targets for drug development. The development of new drugs is hampered by the high costs. A new drug may on an average require 150 miljon ECU’s before registration. The imaging techniques now provides a potential to speed up and reduce costs for this development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Karlsson P, Farde L, Halldin C, Sedvall G, Skrumsager B, Foged C. [11C]NNC687 and [11C]NNC756 as radioligands for PET-determination of central Dl-dopamine receptors. Psychopharmacol 1993;113:149–156.
Karlsson P, Farde L, Halldin C, Sedvall G, Ynddal L, Sloth-Nielsen M. Oral administration of NNC 756 - a placebo controlled PET study of Dl-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology In press.
Farde L, Wiesel F-A, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71–76.
Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. PET-analysis of central D1- and d2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538–544.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Farde, L. (1995). PET in Neuropsychiatric Drug Development. In: Comar, D. (eds) PET for Drug Development and Evaluation. Developments in Nuclear Medicine, vol 26. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0429-6_4
Download citation
DOI: https://doi.org/10.1007/978-94-011-0429-6_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4191-1
Online ISBN: 978-94-011-0429-6
eBook Packages: Springer Book Archive